

## CIIA Publications

1. Veneziani AC, Lheureux S, Millar DG, Dhani N, Colombo I, Madariaga A, Soberanis Pina P, Atale S, Chan YL, Lee J, Ramsahai J, Quintos J, Wang L, Li X, Bowering V, Ohashi P, Wang B, Oza AM. [Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial](#). Nat Commun. 2026 May 14. doi: 10.1038/s41467-026-72125-0.
2. Ihara F, Ohashi Y, Zheng EYF, Fukao S, Rodrigo R, Noamani B, Boukhaled GM, Wang BX, Han DH, Wei X, Burt BD, Saso K, Matsunaga Y, Ly D, Kagoya Y, Butler MO, Mak TW, Saibil SD, Hirano N. [CD28-driven ex vivo generation of stem-like memory CD8<sup>+</sup> T cells bypassing CD3/TCR signaling](#). Proc Natl Acad Sci U S A. 2026 Apr 28;123(17):e2524626123.
3. Said BI, Boukhaled GM, Lok BH, Lukovic J, Mesci A, Waldron J, Wong P, Wang BX, Brooks DG, Milosevic M. [Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy](#). Int J Radiat Oncol Biol Phys. 2026 Feb 1;124(2):441-450.
4. Rose AAN, Maxwell J, Rousselle E, Mukonoweshuro CL, Elkholi IE, Riaud M, Biondini M, Cianfarano E, Soria-Bretones I, Tobin C, McGuire M, Law RWY, Elia AJ, Wang BX, King I, Zhang T, Pugh TJ, Kamil ZS, Butler M, Shepherd FA, Leighl NB, Razak AA, Hansen A, Saibil SD, Bedard PL, Siegel PM, Siu LL, Cescon DW, Spreafico A. [Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial](#). Nat Commun. 2026 Jan 3;17(1):1323.
5. O'Kane GM, Mesci A, Jang RW, Barry A, Bocaya CM, Boukhaled GM, Acton H, Doddington D, Rodrigo R, Chan LML, Noamani B, Harvey H, Elia A, Law R, Prince R, Doherty M, Dodd A, Wong DK, Wang L, Wang BX, Chen EX, Dawson LA, Knox JJ. [Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial \(PEMRAD\)](#). JHEP Rep. 2025 Nov 1;8(2):101658.
6. Garg V, Prokopec SD, Stone SC, Pakbaz S, Chen ML, Lam B, Benito CC, McMullen M, Lungu I, Rossi SD, Msan A, Bowering V, Sotov V, Tran C, Butler MO, Oza AM, Diamandis P, Wang BX, Lheureux S. [Elucidating divergent biology in uterine carcinosarcoma](#). Transl Oncol. 2025 Nov;61:102506.
7. Soleimani S, Li X, Wang BX, Pedersen S, Bruce JP, Eagles J, Liu ZA, Bratman SV, Butler MO, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak A, Siu LL, Ohashi PS, Pugh TJ. [T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab](#). Cell Rep. 2025 Sep 23;44(9):116190.
8. Wu Y, Wu BZ, Ellenbogen Y, Kant JBY, Yu P, Li X, Caloren L, Sotov V, Tran C, Restrepo M, Kushida M, Ayyadhury S, Kossinna P, Lau R, Habibi P, Mansouri S, Regala J, Durbic T, Aboualizabeth F, Tsao J, Ketela T, Pugh T, Butler MO, Wang BX, Dirks PB, Gao A, Zadeh G, Gaiti F. [Neurodevelopmental hijacking of oligodendrocyte lineage programs drives glioblastoma infiltration](#). Dev Cell. 2025 May 13:S1534-5807(25)00260-6.
9. Sanchez Vasquez JD, Nkongolo S, Traum D, Sotov V, Kim SC, Mahamed D, Mehrotra A, Patel A, Chen DY, Fung S, Gaggar A, Feld JJ, Chang KM, Wallin JJ, Wang BX, Janssen H, Gehring AJ. [Virus-associated inflammation imprints an inflammatory profile on monocyte-derived macrophages in the human liver](#). J Clin Invest. 2025 Apr 15;135(8):e175241.
10. Chung DC, Shakfa N, Vakharia J, Warner K, Jacquilot N, Sayad A, Han S, Ghaedi M, Garcia-Batres CR, Sotty J, Azarmina A, Nowlan F, Chen ELY, Zon M, Elford AR, Wang BX, Nguyen LT, Mrkonjic M, Clarke BA, Bernardini MQ, Haibe-Kains B, Ferguson SE, Crome SQ, Jackson HW, Ohashi PS. [CD103+CD56<sup>+</sup> ILCs Are Associated with an Altered CD8<sup>+</sup> T-cell Profile within the Tumor Microenvironment](#). Cancer Immunol Res. 2025 Apr 2;13(4):527-546.
11. Wong MK, Boukhaled GM, Armstrong E, Liu R, Heirali AA, Yee NR, Tsang J, Spiliopoulou P, Schneeberger PHH, Wang BX, Cochrane K, Sherriff K, Allen-Vercoe E, Siu LL, Spreafico A, Coburn B. [Microbial Ecosystem Therapeutics 4 \(MET4\) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors](#). J Immunother Cancer. 2025 Mar 22;13(3):e010681.
12. Hernando-Calvo A, Han M, Ayodele O, Wang BX, Bruce JP, Abbas-Aghababazadeh F, Vila-Casadesús M, Sanz-Garcia E, Yang SYC, Berman HK, Vivancos A, Lam B, Lungu I, Salawu A, Stayner LA, Haibe-Kains B, Bedard PL, Avery L, Razak ARA, Pugh TJ, Spreafico A, Siu LL, Hansen AR. [A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer](#). Clin Colorectal Cancer. 2024 Sep;23(3):272-284.

13. Chung DC, Garcia-Batres CR, Millar DG, Wong SWY, Elford AR, Mathews JA, Wang BX, Nguyen LT, Shaw PA, Clarke BA, Bernardini MQ, Sacher AG, Crome SQ, Ohashi PS. [Generation of an Inhibitory NK Cell Subset by TGF- \$\beta\$ 1/IL-15 Polarization](#). J Immunol. 2024 Jun 15;212(12):1904-1912.
14. Chung DC, Ghaedi M, Warner K, Sayad A, Saibil SD, Bernardini MQ, Clarke BA, Shaw PA, Butler MO, Easson A, Morrissy S, Wang BX, Nguyen L, Ohashi PS, Jacquelot N. [Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors](#). Oncoimmunology. 2024 May 10;13(1):2349347.
15. Lien SC, Ly D, Yang SYC, Wang BX, Clouthier DL, St Paul M, Gadalla R, Noamani B, Garcia-Batres CR, Boross-Harmer S, Bedard PL, Pugh TJ, Spreafico A, Hirano N, Razak ARA, Ohashi PS. [Tumor reactive  \$\gamma\delta\$  T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient](#). Nat Commun. 2024 Feb 6;15(1):1094.
16. Salawu A, Wang BX, Han M, Geady C, Heirali A, Berman HK, Pfister TD, Hernando-Calvo A, Al-Ezzi EM, Stayner LA, Gupta AA, Ayodele O, Lam B, Hansen AR, Spreafico A, Bedard PL, Butler MO, Avery L, Coburn B, Haibe-Kains B, Siu LL, Abdul Razak AR. [Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial](#). Clin Cancer Res. 2023 Oct 13;29(20):4128-4138.
17. Millar DG, Yang SYC, Sayad A, Zhao Q, Nguyen LT, Warner K, Sangster AG, Nakatsugawa M, Murata K, Wang BX, Shaw P, Clarke B, Bernardini MQ, Pugh T, Thibault P, Hirano N, Perreault C, Ohashi PS. [Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire](#). Cancer Immunol Immunother. 2023 Jul;72(7):2375-2392.
18. Spreafico A, Heirali AA, Araujo DV, Tan TJ, Oliva M, Schneeberger PHH, Chen B, Wong MK, Stayner LA, Hansen AR, Saibil SD, Wang BX, Cochrane K, Sherriff K, Allen-Vercoe E, Xu W, Siu LL, Coburn B. [First-in-class Microbial Ecosystem Therapeutic 4 \(MET4\) in combination with immune checkpoint inhibitors in patients with advanced solid tumors \(MET4-IO trial\)](#). Ann Oncol. 2023 Jun;34(6):520-530.
19. Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL. [Targeting the Inducible T-cell Costimulator \(ICOS\) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma](#). Clin Cancer Res. 2023 May 15;29(10):1869-1878.
20. Spiliopoulou P, Janse van Rensburg HJ, Avery L, Kulasingam V, Razak A, Bedard P, Hansen A, Chruscinski A, Wang B, Kulikova M, Chen R, Speers V, Nguyen A, Lee J, Coburn B, Spreafico A, Siu LL. [Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy](#). Cell Death Dis. 2023 Jan 20;14(1):49.
21. Gadalla R, Boukhaled GM, Brooks DG, Wang BX. [Mass cytometry immunostaining protocol for multiplexing clinical samples](#). STAR Protoc. 2022 Aug 22;3(3):101643.
22. Boukhaled GM, Gadalla R, Elsaesser HJ, Abd-Rabbo D, Quevedo R, Yang SYC, Guo M, Wang BX, Noamani B, Gray D, Lau SCM, Taylor K, Aung K, Spreafico A, Hansen AR, Saibil SD, Hirano N, Guidos C, Pugh TJ, McGaha TL, Ohashi PS, Sacher AG, Butler MO, Brooks DG. [Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy](#). Nat Immunol. 2022 Aug;23(8):1273-1283.
23. Watson GA, Sanz-Garcia E, Zhang WJ, Liu ZA, Yang SC, Wang B, Liu S, Kubli S, Berman H, Pfister T, Genta S, Spreafico A, Hansen AR, Bedard PL, Lheureux S, Abdul Razak A, Cescon D, Butler MO, Xu W, Mak TW, Siu LL, Chen E. [Increase in serum choline levels predicts for improved progression-free survival \(PFS\) in patients with advanced cancers receiving pembrolizumab](#). J Immunother Cancer. 2022 Jun;10(6):e004378.
24. Spiliopoulou P, Yang SYC, Bruce JP, Wang BX, Berman HK, Pugh TJ, Siu LL. [All is not lost: learning from 9p21 loss in cancer](#). Trends Immunol. 2022 May;43(5):379-390.
25. Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG, Fleming GF. [Translational randomized phase II trial of cabozantinib in combination with](#)

- [nivolumab in advanced, recurrent, or metastatic endometrial cancer](#). J Immunother Cancer. 2022 Mar;10(3):e004233.
26. Oliva M, Chepeha D, Araujo DV, Diaz-Mejia JJ, Olson P, Prawira A, Spreafico A, Bratman SV, Shek T, de Almeida J, R Hansen A, Hope A, Goldstein D, Weinreb I, Smith S, Perez-Ordoñez B, Irish J, Torti D, Bruce JP, Wang BX, Fortuna A, Pugh TJ, Der-Torossian H, Shazer R, Attanasio N, Au Q, Tin A, Feeney J, Sethi H, Aleshin A, Chen I, Siu L. [Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study](#). J Immunother Cancer. 2021 Oct;9(10):e003476.
  27. Yang SYC, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafallo MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Haibe-Kains B, Brooks DG, McGaha T, Butler M, Bratman SV, Ohashi PS, L Siu LL, Pugh TJ. [Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity](#). Nat Immunol. 2021 Aug;23(8):1273-1283.
  28. Taylor K, Loo Yau H, Chakravarthy A, Wang B, Shen SY, Ettayebi I, Ishak CA, Bedard PL, Abdul Razak A, R Hansen A, Spreafico A, Cescon D, Butler MO, Oza AM, Lheureux S, Stjepanovic N, Van As B, Boross-Harmer S, Wang L, Pugh TJ, Ohashi PS, Siu LL, De Carvalho DD. [An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors](#). J Immunother Cancer. 2020 Aug;8(2):e000883.
  29. MacGregor HL, Sayad A, Elia A, Wang BX, Katz SR, Shaw PA, Clarke BA, Crome SQ, Robert-Tissot C, Bernardini MQ, Nguyen LT, Ohashi PS. [High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer](#). J Immunother Cancer. 2019; 2019 Dec 31;7(1):357.
  30. Gadalla R, Noamani B, MacLeod B, Dickson R, Guo M, Xu W, Lukhele S, Elsaesser HJ, Razak A, Hirano N, McGaha TL, Wang BX, Butler M, Guidos CJ, Ohashi PS, Siu LL, Brooks DG. [Validation of CyTOF against flow cytometry for immunological studies and monitoring of human cancer clinical trials](#). Front Oncol. 2019;9:415.
  31. Jiang DM, Fyles A, Nguyen L, Neel B, Sacher A, Rottapel R, Wang BX, Ohashi PS, Sridhar SS. [Phase I Study of Local Radiation and Tremelimumab in Patients with Inoperable Locally Recurrent or Metastatic Breast Cancer](#). Oncotarget. 2019;10(31):2947-2958.
  32. Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL. [An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation \(INSPIRE\)](#). J Immunother Cancer. 2019 Mar 13;7(1):72.